张小辉;李睿;滕飞;姜金;滕元君;汉华;吴萌;夏亚一;

• 1:兰州大学第二医院骨科
• 2:甘肃省骨关节疾病重点实验室

摘要(Abstract)：

[目的]荟萃分析A型肉毒杆菌素治疗膝骨性关节炎(KOA)的有效性和安全性。[方法]检索PubMed、Embase、The Cochrane Library、Web of Science、CBM、万方数据库和CNKI数据库,搜集A型肉毒杆菌素治疗膝骨性关节炎的研究。经由2名评价员独立筛选文献、提取资料并评价偏倚风险后,采用Stata14.0软件进行荟萃分析。[结果]经过初检、筛选和精读全文后共纳入7个RCT,包括535例患者。荟萃分析结果显示:与对照组相比,A型肉毒杆菌素可显著降低KOA 4周WOMAC疼痛评分[WMD=-9.83,95%CI (-11.79,-7.88),P<0.001]、4周WOMAC僵硬程度评分[WMD=-5.44,95%CI (-7.10,-3.78),P<0.001]、4周WOMAC功能障碍评分[WMD=-4.43,95%CI (-6.00,-2.87),P<0.001],8周WOMAC疼痛评分[WMD=-14.29,95%CI (-25.04,-3.54),P=0.009]、8周WOMAC僵硬程度评分[WMD=-5.33,95%CI (-8.54,-2.12),P<0.001]和8周WOMAC功能障碍评分[WMD=-7.99,95%CI (-12.71,-3.27),P<0.001],差异均有统计学意义。[结论]当前证据表明A型肉毒杆菌素可减轻膝关节疼痛,有效治疗膝骨性关节炎,受纳入研究质量的限制,上述结论尚需更多临床随机对照试验予以验证。

关键词(KeyWords)： 肉毒杆菌素;肉毒毒素;骨性关节炎;荟萃分析

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(编号:81874017和81672207);; 甘肃省中医药管理局科研项目(编号:GZK-2017-51);; 兰州市科技计划项目(编号:2017-4-88和2018-3-52);; “中央高校基本科研业务费专项资金”重点研究基地创新项目(编号:lzujbky-2018-kb16);; 兰州大学第二医院“萃英科技创新”计划项目(编号:CY2017-QN11、CY2017-ZD02和CY2017-QN12)

作者(Author): 张小辉;李睿;滕飞;姜金;滕元君;汉华;吴萌;夏亚一;

Email:

DOI:

参考文献(References)：

• [1]Ikeuchi M, Izumi M, Aso K, et al. Clinical characteristics of pain originating from intra-articular structures of the knee joint in patients with medial knee osteoarthritis[J]. Springerplus, 2013, 2(1):628.
• [2]Kavchak AJE, Fernández-De-Las-Pe?as C, et al. Association between altered somatosensation, pain, and knee stability in patients with severe knee osteoarthrosis[J]. Clin J Pain, 2012, 28(7):589-594.
• [3]Barron MC, Rubin BR. Managing osteoarthritic knee pain[J]. J Am Osteopathic Assoc, 2007;107(Supplement 6):ES21.
• [4]Arendt Nielsen L, Egsgaard LL, Petersen KK, et al. A mechanism based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levels[J]. Eur J Pain,2015, 19(10):1406-1417.
• [5]Zavodovsky B, Sivordova L, Polyakova YV, et al. The efficacy and safety of etoricoxib versus meloxicam in the treatment of patients with gonarthrosis[J]. Terapevticheskii Arkhiv, 2016, 88(12):78-81.
• [6]Matsuse H, Hashida R, Takano Y, et al. Walking exercise simulta-neously combined with neuromuscular electrical stimulation of antagonists resistance improved muscle strength, physical function,and knee pain in symptomatic knee osteoarthritis:a single-arm study[J]. J Strength Conditioning Res, 2017, 31(1):171-180.
• [7]?olak TK, Kavlak B, Aydo du O, et al. The effects of therapeutic exercises on pain, muscle strength, functional capacity, balance and hemodynamic parameters in knee osteoarthritis patients:a randomized controlled study of supervised versus home exercises[J].Rheumatol Int, 2017, 37(3):399-407.
• [8]Santos WTd, Rodrigues EdC, Mainenti MRM. Muscle performance, body fat, pain and function in the elderly with arthritis[J].Acta Ortop Brasil, 2014, 22(1):54-58.
• [9]Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain:a randomized, doubleblinded, placebo-controlled trial[J]. Translational Res, 2009, 153(5):205-216.
• [10]McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee:results of a placebo-controlled, doubleblind study[J]. Osteoarthritis Cartilage, 2018, 1:1-10.
• [11]Bao X, Tan JW, Flyzik M, et al. Effect of therapeutic exercise on knee osteoarthritis after intra-articular injection of botulinum toxin type A, hyaluronate or saline:a randomized controlled trial[J]. J Rehabil Med, 2018, 50(6):534-541.
• [12]Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0[S]. The Cochrane Collaboration. Confidence intervals2011.
• [13]Boon AJ, Smith J, Dahm DL, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis:a pilot study[J].PM&R, 2010, 2(4):268-276.
• [14]Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis[J]. PM&R, 2016, 8(12):1127-1135.
• [15]Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty:a randomized controlled trial[J]. J Rheumatol, 2010, 37(11):2377-2386.
• [16]Arendt-Nielsen L, Jiang GL, DeGryse R, et al. Intra-articular on abotulinum toxin A in osteoarthritis knee pain:effect on human mechanistic pain biomarkers and clinical pain[J]. Scand J Rheumatol, 2017, 46(4):303-316.
• [17]鲍晓,谭杰文,王鸣鸿,等. A型肉毒毒素用于膝骨性关节炎治疗的临床疗效[J].中国康复医学杂志, 2015, 30(8):808-810.
• [18]Agafonova NV, Khasanova DR. The use of different doses of botulotoxin A in the treatment of early arm poststroke spasticity[J]. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova, 2014, 114(10):68-71.
• [19]Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA(Dysport(R))to incobotulinumtoxinA(Xeomin(R))botulinum toxin formulation:a review of 257 cases[J]. J Rehabil Med, 2015,47(2):183-186.
• [20]Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia:observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial[J]. J Headache Pain, 2014:27(15):65.
• [21]De Andres J, Adsuara VM, Palmisani S, et al. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans[J]. Regional Anesthesia Pain Med, 2010, 35(3):255-260.
• [22]Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain:a randomized, double-blind study[J]. Neurology, 2001, 56(10):1290-1293.
• [23]Gazerani P, Au S, Dong X, et al. Botulinum neurotoxin type A(BoNTA)decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis[J]. Pain, 2010, 151(3):606-616.
• [24]Guo BL, Zheng CX, Sui BD, et al. A closer look to botulinum neurotoxin type A-induced analgesia[J]. Toxicon, 2013, 71:134-139.
• [25]Tajti J, Szok D, Tuka B, et al. Botulinum neurotoxin-a therapy in migraine[J]. Ideggyogyaszati Szemle, 2012, 65(3-4):77-82.
• [26]Aurora SK, Dodick DW, Diener HC, et al. OnabotulinumtoxinA for chronic migraine:efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program[J]. Acta Neurologica Scandinavica, 2014, 129(1):61-70.
• [27]Wu T, Song HX, Dong Y, et al. Intra-articular injections of botulinum toxin a for refractory joint pain:a systematic review and metaanalysis[J]. Clin Rehabil, 2017, 31(4):435-443.